Alterity Therapeutics Limited
Price Action
Technical Summary
EMERGING TRENDAlterity Therapeutics Limited is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 87), indicating clear outperformance against the broad market. Earnings growth of 36% provides fundamental context to the price action. However, price is extended 21% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.84 | +13.32% | ABOVE |
| 50 SMA | $4.55 | +20.63% | ABOVE |
| 100 SMA | $4.09 | +34.29% | ABOVE |
| 150 SMA | $3.82 | +43.76% | ABOVE |
| 200 SMA | $3.91 | +40.56% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ATHE in an uptrend right now?
ATHE has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ATHE overbought or oversold?
ATHE's RSI (14) is 74. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is ATHE outperforming the market?
ATHE has a Relative Strength (RS) Rating of 87 out of 99. Yes, ATHE is a market leader, outperforming 87% of all stocks over the past 12 months.
Where is ATHE in its 52-week range?
ATHE is trading at $5.49, which is 78% of its 52-week high ($7.00) and 65% above its 52-week low ($2.66).
How volatile is ATHE?
ATHE has a Beta of 1.26 and 52-week volatility of 70%. It's more volatile than the S&P 500 - expect bigger swings.